Is Ozempic a Peptide? 2026 Data on GLP-1 Drug Composition, Market Growth, and Industry Comparisons
Published: July 8, 2026 21:39
Author: Anjali Dalton
Abstract: Ozempic (semaglutide) is a synthetic peptide-based GLP-1 receptor agonist, not a natural peptide. 2026 data confirms its composition as a 31-amino acid analog with enhanced half-life. The GLP-1 drug market is projected to exceed $100 billion, driven by obesity and diabetes demand. Comparative studies show superior efficacy over liraglutide and dulaglutide. Industry insights guide selection based on dosing frequency, tolerability, and cost. Understanding peptide structure is critical for regulatory and formulation decisions.